Swiss biotech firm BioVersys plans IPO at SIX Swiss Exchange in first quarter 2025

21.01.2025 14:20, Rita Longobardi

Marc Gitzinger participated with his startup idea in 2007 in the Venturelab Venture Challenge course at ETH Zurich to lay the foundation for his biotech company. With the support of Venture Kick in 2008 BioVersys was incorporated and participated in the same year in the Venture Leaders business development roadshow to Boston. 17 years later, BioVersys has raised in total of 130 million from investors and announced the intention to float on the SIX Swiss Exchange in 2025.

BioVersys AG is a multi-asset, clinical-stage Swiss biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria.  It all started in 2007 when ETH student Marc Gitzinger participated with his startup idea 2007 in the Venturelab Venture Challenge semester course at ETH Zurich to learn how to start a biotech company. With the support of Venture Kick in 2008 he received CHF 130’000 to incorporate BioVersys. In the same year, Gitzinger participated in the Venture Leaders business development roadshow in Boston to take the first step to go global.                                                                                                             
                                                                                                                                                                                     

---

---

Today, BioVersys has raised in total130 million from investors and has BV100 and Alpibectir two drug candidates in their portfolio that address two of the top three priorities of the World Health Organization (WHO) for bacterial pathogens to prevent a global health crisis. The Swiss biotech company intends to have its shares admitted to trading and listed on the SIX Swiss Exchange in the first quarter of 2025 and plans to raise CHF 80 million. Dr. Marc Gitzinger, CEO of BioVersys: “The envisaged listing on the Swiss Stock Exchange represents a key milestone for our company since its inception. We plan to use the proceeds to primarily advance BV100 through Phase 3 clinical development and regulatory submission and advance the clinical development for Alpibectir together with our partner GSK to reach the next critical clinical milestone.” BioVersys was awarded several years with the TOP 100 Swiss Startups label and participated in 2022 in the first SIX IPO Academy to prepare and equip TOP 100 scaleups for a potential IPO on the Swiss Stock Exchange.

"As a scientific founder, the educational programs that are organized and co-organized by Venturelab, such as the SIX IPO Academy, provide very valuable toolboxes that you need during your entrepreneurial path," stated Marc Gitzinger, Co-Founder and CEO of BioVersys.


Dr. Sergio Lociuro (Chief Scientific Officer) and Marc Gitzinger (CEO)